Chelsea Therapeutics stock halted ahead of crucial meeting

|About: Chelsea Therapeutics Inte... (CHTP)|By:, SA News Editor

Shares in Chelsea Therapeutics (CHTP) have been halted ahead of a second meeting of an FDA advisory board over the company's Northera treatment for hypotension.

A meeting in February 2012 voted 7-4 to recommend approving the drug, but the FDA rejected the therapy anyway.

The latest panel comes after the agency accepted an appeal from Chelsea Therapeutics.